Variable | Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Sex (men vs. women) | 1.204 (0.806–1.799) | 0.363 |  |  |
Age (<65 vs. ≥65 years) | 0.999 (0.983–1.016) | 0.934 |  |  |
Pathologic type (ccRCC vs. nccRCC) | 1.408 (0.896–2.221) | 0.138 |  |  |
History of nephrectomy (yes vs. no) | 1.103 (0.691–1.760) | 0.681 |  |  |
History of cytokine treatment (yes vs. no) | 0.963 (0.667–1.391) | 0.842 |  |  |
Fuhrman grade (1–2 vs. 3–4 and unknown) | 1.620 (1.260–2.081) | <0.001* | 1.491 (1.147–1.937) | 0.003 |
Number of metastatic sites (1 vs. ≥ 2) | 2.010 (1.384–2.918) | <0.001* | 1.734 (1.162–2.588) | 0.007 |
MSKCC risk category (favorable and intermediate vs. poor) | 1.927 (1.548–2.399) | <0.001* | 2.236 (1.747–2.862) | <0.001 |
NLR (continuous variable) | 1.163 (1.085–1.247) | <0.001* | 1.113 (1.034–1.199) | 0.005 |
Drug category (sorafenib vs. sunitinib) | 1.036 (0.725–1.480) | 0.847 |  |  |
Pre-treatment serum albumin level (continuous variable) | 0.962 (0.934–0.992) | 0.012* | 1.008 (0.970–1.047) | 0.691 |
Post-treatment serum albumin level (continuous variable) | 0.952 (0.930–0.974) | <0.001 | 0.967 (0.941–0.994) | 0.016 |